Eugene L Stewart
Overview
Explore the profile of Eugene L Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, et al.
Antimicrob Agents Chemother
. 2023 Feb;
67(3):e0032622.
PMID: 36794938
No abstract available.
2.
Vavro C, Ruel T, Wiznia A, Montanez N, Nangle K, Horton J, et al.
Antimicrob Agents Chemother
. 2021 Oct;
66(1):e0164521.
PMID: 34694878
P1093 is a multicenter, open-label, phase I/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4 weeks to <18 years with...
3.
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, et al.
Antimicrob Agents Chemother
. 2021 Oct;
66(1):e0164321.
PMID: 34694877
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic...
4.
Schulte C, Deaton D, Diaz E, Do Y, Gampe R, Guss J, et al.
Bioorg Med Chem Lett
. 2021 May;
47:128113.
PMID: 33991628
Through an internal virtual screen at GlaxoSmithKline a distinct class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors were discovered. Careful evaluation of crystal structures and SAR led to a novel, potent, and orally...
5.
Frederick D, McDougal A, Semenas M, Vappiani J, Nuzzo A, Ulrich J, et al.
Skelet Muscle
. 2020 Oct;
10(1):30.
PMID: 33092650
Background: Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder stemming from a loss of functional dystrophin. Current therapeutic options for DMD are limited, as small molecule modalities remain...
6.
Cadilla R, Deaton D, Do Y, Elkins P, Ennulat D, Guss J, et al.
Bioorg Med Chem
. 2020 Oct;
28(23):115791.
PMID: 33059303
GlaxoSmithKline and Astex Pharmaceuticals recently disclosed the discovery of the potent H-PGDS inhibitor GSK2894631A 1a (IC = 9.9 nM) as part of a fragment-based drug discovery collaboration with Astex Pharmaceuticals....
7.
Deaton D, Do Y, Holt J, Jeune M, Kramer H, Larkin A, et al.
Bioorg Med Chem
. 2019 Mar;
27(8):1456-1478.
PMID: 30858025
With the goal of discovering more selective anti-inflammatory drugs, than COX inhibitors, to attenuate prostaglandin signaling, a fragment-based screen of hematopoietic prostaglandin D synthase was performed. The 76 crystallographic hits...
8.
Deaton D, Haffner C, Henke B, Jeune M, Shearer B, Stewart E, et al.
Bioorg Med Chem
. 2018 Mar;
26(8):2107-2150.
PMID: 29576271
Starting from 4-amino-8-quinoline carboxamide lead 1a and scaffold hopping to the chemically more tractable quinazoline, a systematic exploration of the 2-substituents of the quinazoline ring, utilizing structure activity relationships and...
9.
Zhong H, Stewart E, Kontoyianni M, Phillip Bowen J
J Chem Theory Comput
. 2015 Dec;
1(2):230-8.
PMID: 26641293
The potential energy surfaces (PES) of 2-butanone, 2-butanimine, 1-butenamine, propanal, and propanimine have been explored with ab initio and DFT calculations at the RHF/6-311G**, MP2/6-311G**, and B3LYP/6-311G** levels of theory....
10.
Becherer J, Boros E, Carpenter T, Cowan D, Deaton D, Haffner C, et al.
J Med Chem
. 2015 Aug;
58(17):7021-56.
PMID: 26267483
Starting from the micromolar 8-quinoline carboxamide high-throughput screening hit 1a, a systematic exploration of the structure-activity relationships (SAR) of the 4-, 6-, and 8-substituents of the quinoline ring resulted in...